These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 28910175)

  • 1. Neurotrophic Keratopathy: Therapeutic Approach Using a Novel Matrix Regenerating Agent.
    Guerra M; Marques S; Gil JQ; Campos J; Ramos P; Rosa AM; Quadrado MJ; Murta JN
    J Ocul Pharmacol Ther; 2017 Nov; 33(9):662-669. PubMed ID: 28910175
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Topical treatment with a new matrix therapy agent (RGTA) for the treatment of corneal neurotrophic ulcers.
    Aifa A; Gueudry J; Portmann A; Delcampe A; Muraine M
    Invest Ophthalmol Vis Sci; 2012 Dec; 53(13):8181-5. PubMed ID: 23150626
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Matrix Regeneration Therapy: A Case Series of Corneal Neurotrophic Ulcers.
    Arvola RP; Robciuc A; Holopainen JM
    Cornea; 2016 Apr; 35(4):451-5. PubMed ID: 26845313
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Topical Recombinant Human Nerve Growth Factor (Cenegermin) for Neurotrophic Keratopathy: A Multicenter Randomized Vehicle-Controlled Pivotal Trial.
    Pflugfelder SC; Massaro-Giordano M; Perez VL; Hamrah P; Deng SX; Espandar L; Foster CS; Affeldt J; Seedor JA; Afshari NA; Chao W; Allegretti M; Mantelli F; Dana R
    Ophthalmology; 2020 Jan; 127(1):14-26. PubMed ID: 31585826
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Healing of resistant corneal neurotrophic ulcers using a matrix regenerating agent.
    Cochener B; Zagnoli C; Hugny-Larroque C; Derrien S
    J Fr Ophtalmol; 2019 Feb; 42(2):159-165. PubMed ID: 30573293
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of new biomimetic regenerating agents on corneal wound healing in an experimental model of post-surgical corneal ulcers.
    Alcalde I; Íñigo-Portugués A; Carreño N; Riestra AC; Merayo-Lloves JM
    Arch Soc Esp Oftalmol; 2015 Oct; 90(10):467-74. PubMed ID: 26101128
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of corneal epithelial wound healing after penetrating keratoplasty in patients receiving a new matrix therapy agent (regenerating agent).
    Jullienne R; Garcin T; Crouzet E; He Z; Renault D; Thuret G; Gain P
    Eur J Ophthalmol; 2020 Jan; 30(1):119-124. PubMed ID: 30378440
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Pilot study of a new matrix therapy agent (RGTA OTR4120) in treatment-resistant corneal ulcers and corneal dystrophy].
    Chebbi CK; Kichenin K; Amar N; Nourry H; Warnet JM; Barritault D; Baudouin C
    J Fr Ophtalmol; 2008 May; 31(5):465-71. PubMed ID: 18641578
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pediatric Use of Recombinant Human Nerve Growth Factor 20 μg/mL Eye Drops (Cenegermin) for Bilateral Neurotrophic Keratopathy in Congenital Corneal Anesthesia.
    Leto MG; Toro ME; Indemini PE; Fruttero C; Denina M; Dalmazzo C; Sannia A; Vaiano AS
    Cornea; 2021 Feb; 40(2):228-231. PubMed ID: 33201057
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Topical Treatment of Persistent Epithelial Defects with a Matrix Regenerating Agent.
    Sevik MO; Turhan SA; Toker E
    J Ocul Pharmacol Ther; 2018 Nov; 34(9):621-627. PubMed ID: 30312119
    [TBL] [Abstract][Full Text] [Related]  

  • 11. RGTA in corneal wound healing after transepithelial laser ablation in a rabbit model: a randomized, blinded, placebo-controlled study.
    Xeroudaki M; Peebo B; Germundsson J; Fagerholm P; Lagali N
    Acta Ophthalmol; 2016 Nov; 94(7):685-691. PubMed ID: 27227481
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Topical treatment with nerve growth factor for corneal neurotrophic ulcers.
    Lambiase A; Rama P; Bonini S; Caprioglio G; Aloe L
    N Engl J Med; 1998 Apr; 338(17):1174-80. PubMed ID: 9554857
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of a New Matrix Therapy Agent in Persistent Epithelial Defects After Bacterial Keratitis Treated With Topical Fortified Antibiotics.
    Chappelet MA; Bernheim D; Chiquet C; Aptel F
    Cornea; 2017 Sep; 36(9):1061-1068. PubMed ID: 28691943
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Restoration of corneal epithelial barrier function and wound healing by substance P and IGF-1 in rats with capsaicin-induced neurotrophic keratopathy.
    Nakamura M; Kawahara M; Nakata K; Nishida T
    Invest Ophthalmol Vis Sci; 2003 Jul; 44(7):2937-40. PubMed ID: 12824234
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A comparison of the efficacy of autologous serum eye drops with amniotic membrane transplantation in neurotrophic keratitis.
    Turkoglu E; Celik E; Alagoz G
    Semin Ophthalmol; 2014 May; 29(3):119-26. PubMed ID: 23758337
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fast and sustained healing of resistant corneal ulcers using corneal scrubbing and matrix regenerating therapy.
    Lazreg S; Labetoulle M; Renault D; Baudouin C
    Eur J Ophthalmol; 2021 May; 31(3):959-966. PubMed ID: 32345041
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Management of corneal neurotrophic ulcers with Cacicol®-RGTA (ReGeneraTing Agent): a case series.
    Salazar-Quiñones L; Molero-Senosiáin M; Aguilar-Munoa S; Gegúndez-Fernández JA; Díaz-Valle D; Muñoz-Hernández AM; Benítez-Del-Castillo JM
    Arch Soc Esp Oftalmol (Engl Ed); 2020 Sep; 95(9):421-428. PubMed ID: 32563627
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Persistent epithelial defects due to neurotrophic keratopathy treated with a substance p-derived peptide and insulin-like growth factor 1.
    Nishida T; Chikama T; Morishige N; Yanai R; Yamada N; Saito J
    Jpn J Ophthalmol; 2007; 51(6):442-7. PubMed ID: 18158595
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Management of herpes zoster neurotrophic ulcer using a new matrix therapy agent (RGTA): A case report].
    De Monchy I; Labbé A; Pogorzalek N; Gendron G; M'Garrech M; Kaswin G; Labetoulle M
    J Fr Ophtalmol; 2012 Mar; 35(3):187.e1-6. PubMed ID: 22015067
    [TBL] [Abstract][Full Text] [Related]  

  • 20. RGTA-based matrix therapy in severe experimental corneal lesions: safety and efficacy studies.
    Brignole-Baudouin F; Warnet JM; Barritault D; Baudouin C
    J Fr Ophtalmol; 2013 Nov; 36(9):740-7. PubMed ID: 23958066
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.